Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.
Hölting TLB, Cidre-Aranaz F, Matzek D, Popper B, Jacobi SJ, Funk CM, Geyer FH, Li J, Piseddu I, Cadilha BL, Ledderose S, Zwilling J, Ohmura S, Anz D, Künkele A, Klauschen F, Grünewald TGP, Knott MML. Hölting TLB, et al. Among authors: piseddu i. Mol Cancer. 2022 Oct 13;21(1):199. doi: 10.1186/s12943-022-01641-6. Mol Cancer. 2022. PMID: 36229873 Free PMC article.
Constitutive Expression of CCL22 Is Mediated by T Cell-Derived GM-CSF.
Piseddu I, Röhrle N, Knott MML, Moder S, Eiber S, Schnell K, Vetter V, Meyer B, Layritz P, Kühnemuth B, Wiedemann GM, Gruen J, Perleberg C, Rapp M, Endres S, Anz D. Piseddu I, et al. J Immunol. 2020 Oct 15;205(8):2056-2065. doi: 10.4049/jimmunol.2000004. Epub 2020 Sep 9. J Immunol. 2020. PMID: 32907996
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN. Ben Khaled N, et al. Among authors: piseddu i. Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240. Cancers (Basel). 2022. PMID: 36358659 Free PMC article.
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
Rapp M, Wintergerst MWM, Kunz WG, Vetter VK, Knott MML, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian UH, Endres S, Anz D. Rapp M, et al. Among authors: piseddu i. J Exp Med. 2019 May 6;216(5):1170-1181. doi: 10.1084/jem.20170277. Epub 2019 Mar 25. J Exp Med. 2019. PMID: 30910796 Free PMC article.
CCL1 is a major regulatory T cell attracting factor in human breast cancer.
Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D. Kuehnemuth B, et al. Among authors: piseddu i. BMC Cancer. 2018 Dec 20;18(1):1278. doi: 10.1186/s12885-018-5117-8. BMC Cancer. 2018. PMID: 30572845 Free PMC article.